A
Anca-L. Grosu
Researcher at University of Freiburg
Publications - 55
Citations - 705
Anca-L. Grosu is an academic researcher from University of Freiburg. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 13, co-authored 55 publications receiving 602 citations. Previous affiliations of Anca-L. Grosu include University Medical Center Freiburg & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Salvage Lymph Node Dissection with Adjuvant Radiotherapy for Nodal Recurrence of Prostate Cancer
Cordula A. Jilg,H.C. Rischke,S.N. Reske,Karl Henne,Anca-L. Grosu,Wolfgang Weber,Vanessa Drendel,M. Schwardt,A. Jandausch,Wolfgang Schultze-Seemann +9 more
TL;DR: Based on (11)C/(18)F-choline positron emission tomography-computerized tomography as a diagnostic tool, salvage lymph node dissection is feasible for the treatment of nodal recurrence of prostate cancer.
Journal ArticleDOI
PET for radiation treatment planning of brain tumours.
Anca-L. Grosu,Wolfgang Weber +1 more
TL;DR: There are some data showing that MET-PET and (DOTATOC)-PET can be used for GTV delineation in meningiomas and glomus tumours and the role of PET in the visualization of the biological characteristics of the tumours: proliferation, hypoxia and angiogenesis/peptide expression should be investigated in future studies.
Journal ArticleDOI
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Erica Hlavin Bell,Stephanie L. Pugh,Joseph P. McElroy,Mark R. Gilbert,Minesh P. Mehta,Alexander C. Klimowicz,Anthony M. Magliocco,Markus Bredel,Pierre A. Robe,Anca-L. Grosu,Roger Stupp,Walter J. Curran,Aline Paixão Becker,Andrea L. Salavaggione,Jill S. Barnholtz-Sloan,Kenneth Aldape,Deborah T. Blumenthal,Paul D. Brown,Jonathan D. Glass,Luis Souhami,R. Jeffrey Lee,David Brachman,John C. Flickinger,Minhee Won,Arnab Chakravarti +24 more
TL;DR: This new NRG-GBM-RPA model improves outcome stratification over both the current RTOG RPA model and MGMT promoter methylation, respectively, for patients with GBM treated with radiation and temozolomide and was biologically validated in an independent data set.
Journal ArticleDOI
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation
Ingeborg Tinhofer,Ingeborg Tinhofer,Volker Budach,Volker Budach,Mohammad Saki,Mohammad Saki,Robert Konschak,Robert Konschak,Franziska Niehr,Franziska Niehr,Korinna Jöhrens,Wilko Weichert,Wilko Weichert,Wilko Weichert,Annett Linge,Fabian Lohaus,Mechthild Krause,Konrad Neumann,Volker Endris,Volker Endris,Ali Sak,Martin Stuschke,Panagiotis Balermpas,Claus Rödel,Melanie Avlar,Anca-L. Grosu,Amir Abdollahi,Jürgen Debus,Claus Belka,Claus Belka,Steffi Pigorsch,Steffi Pigorsch,Stephanie E. Combs,Stephanie E. Combs,David Mönnich,David Mönnich,Daniel Zips,Daniel Zips,Michael Baumann +38 more
TL;DR: Distinct mutation profiles in HPV- and HPV+ SCCHN identify subgroups with poor outcome after adjuvant chemoradiation and Mutant p53 and the phosphoinositide 3-kinase pathway were identified as potential druggable targets for subgroup-specific treatment optimisation.
Journal ArticleDOI
Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity.
V. Duncker-Rohr,Ursula Nestle,Felix Momm,V. Prokic,Felix Heinemann,Michael Mix,J. Reusch,M.-B. Messmer,N. Marschner,Cornelius F. Waller,Wolfgang Weber,Anca-L. Grosu +11 more
TL;DR: In this article, the authors report data on 45 lung lesions [non-small cell lung cancer (NSCLC) or metastases] in 39 patients treated between 2009 and 2010 by Stereotactic ablative body radiotherapy (SBRT, SABR) using total doses of 35 Gy (5 fractions) or 375 Gy (3 fractions) prescribed to the 60% isodose line encompassing the planning target volume.